Clinical Trials

Overview

About this study

Achalasia is a rare disorder of the esophagus characterized by absent peristalsis and impaired relaxation of the lower esophageal sphincter. This results in dysphagia, or the inability to swallow, and can lead to malnutrition and failure to thrive in severe disease. POEM has emerged as an effective, minimally invasive therapy for achalasia, enabling selective circular or full thickness myotomy through the distal esophagus, esophagogastric junction (EGJ) and cardia. POEM is a natural orifice transluminal endoscopic surgery (NOTES) alternative to Heller myotomy, and does not involve incisions to the chest or abdomen. This outpatient procedure involves same-day discharge or an overnight stay in the hospital for observation. As a relatively new procedure, long term outcomes are not well defined. Furthermore, issues regarding patient selection for POEM versus Heller myotomy or pneumatic dilation, predictors of treatment response, and assessment of complications following POEM, including  gastroesophageal reflux disease, need to be defined. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information